Open AccessPrediction of mortality in hospitalized Egyptian patients with Coronavirus disease-2019: A multicenter retrospective study
Author(s) -
Muhammad M. AbdelGhaffar,
Dalia Omran,
Ahmed Elgebaly,
Eshak I. Bahbah,
Shimaa Afify,
Mohamed F Alsoda,
Mohamed El-Shiekh,
Enass S. ElSayed,
Soha S. Shaaban,
Samah AbdelHafez,
Khaled ElKelany,
Ayman A. Eltayar,
Omnia Ali,
Lamiaa Kamal,
Ahmed Heiba,
Ahmad El Askary,
Hend Ibrahim Shousha
Publication year - 2022
Publication title -
plos one
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.99
H-Index - 332
ISSN - 1932-6203
DOI - 10.1371/journal.pone.0262348
Subject(s) - medicine , retrospective cohort study , odds ratio , diabetes mellitus , epidemiology , gastroenterology , endocrinology
We aimed to assess the epidemiological, clinical, and laboratory characteristics associated with mortality among hospitalized Egyptian patients with COVID-19. A multicenter, retrospective study was conducted on all polymerase chain reaction (PCR)-confirmed COVID-19 cases admitted through the period from April to July 2020. A generalized linear model was reconstructed with covariates based on predictor’s statistical significance and clinically relevance. The odds ratio (OR) was calculated by using stepwise logistic regression modeling. A total of 3712 hospitalized patients were included; of them, 900 deaths were recorded (24.2%). Compared to survived patients, non-survived patients were more likely to be older than 60 years (65.7%), males (53.6%) diabetic (37.6%), hypertensive (37.2%), and had chronic renal insufficiency (9%). Non-survived patients were less likely to receive azithromycin (p 60 years, comorbidities, tachycardia, hypoxemia, and altered consciousness level are independent predictors of mortality among Egyptian hospitalized patients with COVID-19. On the other hand, the use of anticoagulants and azithromycin is associated with reduced mortality.